Deutsche Bank Names Top Healthcare Stocks Led by DexCom and Insulet

Deutsche Bank initiated coverage on DexCom, Insulet, Tandem Diabetes Care, and Smurfit Westrock, with Buy ratings on DXCM at $86, PODD at $190, and SW at $57. The most supportive calls centered on improving fundamentals, expanding coverage and product adoption in diabetes care, and operational upside at Smurfit Westrock, though Tandem was only rated Hold due to execution risk. Smurfit Westrock also reported Q1 2026 EPS of $0.33 versus expectations, while revenue of $7.71 billion beat estimates.

Analysis

The market is starting to reward the second derivative of diabetes adoption: not just device growth, but reimbursement broadening and operating leverage. The biggest upside asymmetry sits with the category leader that can convert coverage expansion into higher utilization and mix uplift; that creates a self-reinforcing loop where better margins fund more commercial reach, which in turn supports higher valuation multiples. By contrast, the laggard is being valued more like an execution story than a growth story, because the reimbursement transition introduces a multi-quarter evidence gap that investors rarely underwrite generously.

The key competitive question is whether GLP-1 adoption is a net headwind or a screening mechanism. If weight-loss drugs reduce low-conviction users but improve disease awareness and physician engagement, then the addressable market could actually become more premium and stickier over the next 12-24 months. That favors the incumbent platforms with stronger channel control and installed base data, while smaller players may face a higher cost of acquisition and slower payback on product development.

Packaging is the quieter beneficiary here. The thesis is not just cost takeout, but that integration and capital discipline can translate into a structurally higher cash conversion profile, which matters in a slower-growth macro backdrop. The market may still be discounting the durability of synergy capture because it often shows up as gradual margin expansion over 6-8 quarters rather than a single catalyst quarter.

Contrarian risk: the current optimism may be front-running too much of the margin recovery in healthcare and too little of the execution risk in reimbursement transitions and product quality events. If there is any near-term stumble in claims processing, recalls, or guidance cadence, the multiple compression could be abrupt because these names have already rerated off the lows. That argues for owning the best operator and funding it with the weakest monetization path.

Key Decisions for Investors

• Long DXCM vs short TNDM for 3-6 months: own the cleaner reimbursement/scale beneficiary and fade the lower-conviction transition story; target relative outperformance if market keeps rewarding beat-and-raise visibility.
• Buy PODD on pullbacks over the next 4-8 weeks, but hedge with a short-dated put spread: use any weakness tied to recall headlines as entry, since the tape appears to be underpricing durable pump demand and share gains.
• Initiate a long SW position on a 6-12 month horizon: the trade works if integration synergies and EBITDA expansion compound; risk/reward improves if purchased on any post-earnings weakness near support.
• Avoid chasing DXCM after the recent rerating; instead express bullishness via call spreads 3-6 months out to capture continued multiple expansion while limiting downside if utilization data disappoints.
• Monitor reimbursement and claims data across the diabetes basket as the next catalyst set; if pharmacy channel transition gains traction, rotate capital from TNDM into DXCM/PODD because the market will likely reward the clearest operating leverage first.